Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)

PHASE3CompletedINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

May 7, 2014

Primary Completion Date

March 23, 2016

Study Completion Date

February 21, 2017

Conditions
Hepatitis C
Interventions
DRUG

Narlaprevir

yellow film-coated 100 mg. tablets

DRUG

Ritonavir

100 mg tablets encapsulates in gelatin capsules (for blinding purposes)

DRUG

Placebo Narlaprevir

yellow film-coated 100 mg. tablets identical to Narlaprevir tablets

DRUG

Placebo Ritonavir

100 mg lactose/ cellulose tablets encapsulated in gelatin capsules (for blinding purposes) identical to Ritonavir capsules

DRUG

Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b

180µg for subcutaneous injections in 0.5 ml syrettes / 1.5 µg/kg for subcutaneous injections in 50µkg, 80µkg,100µkg, 120µkg, 150µkg in vials

DRUG

Ribavirin

"hard gelatin, white 200mg. capsules~Weight-based dose was 1000 mg/day (patient weight \<75 kg) or 1200 mg/day (patient weight ≥75 kg) with Peginterferon alfa-2a and 800 mg/day (patient weight \<65 kg) - 1400 (patient weight \>105 kg) mg/day with Peginterferon alfa-2b"

Trial Locations (20)

Unknown

South-Ural State Medical University, Clinic of Medical Academy, Infectious Diseases Department, Chelyabinsk

Kazan State Medical Academy, Republican Clinical Hospital of Infectious Diseases n.a. A.F. Agafonov, Kazan'

Federal Budget Science Institution Central Science and Research Institute of Epidemiology of RosPotrebNadzor, Moscow

Federal State Budget Healthcare Institution Central Clinical Hospital of Russian Academy of Science, Moscow

First Moscow State Medical University n.a. I.M. Sechenov, Clinic of Nephrology, Internal and Professional Diseases n.a. E.M. Tarleev, Moscow

First Moscow State Medical University n.a. I.M. Sechenov, Propedeutics of Internal Diseases Department, Moscow

Moscow State Medical Stomatological University n.a. A. I. Evdokimov, Clinical Infectious Hospital #1, Clinical Infections Department, Moscow

"Public Corporation Clinical Hospital of Centrosouze", Moscow

"Public Corporation MedElitConsulting", Moscow

State Budget Healthcare Moscow Institution Clinical Scientific Center of Healthcare Department of Moscow, Moscow

State Budgetary Healthcare Organization Clinical city hospital #24, Moscow

Novosibirsk State Medical University, Clinical city hospital #12, Therapeutic Department, Novosibirsk

Military Medical Academy of Ministry of Defense of Russian Federation n.a. S.M. Kirov, Infectious Diseases Department, Saint Petersburg

Saint Petersburg State Budget Healthcare Institution Center of AIDS and Infectious Diseases Prevention and Control, Saint Petersburg

Saint Petersburg State Budgetary Healthcare Institution Clinical Hospital of Infectious Diseases n.a. S.P. Botkin, Saint Petersburg

Clinic of Samara State Medical University, Department of Infectious Diseases, Samara

"Public corporation Medical company Gepatolog", Samara

Municipal Healthcare Institution Clinical city hospital #2 n.a. V.I. Razumovsky, Infectious Diseases Department, Saratov

Stavropolsky Krai Clinical Hospital, Gastroenterology Department related to Hospital Therapy Department, Stavropol

Stavropolsky State Medical University, Clinic of Gastroenterology, Hepatology and Pancreatology, Stavropol

Sponsors

Lead Sponsor

All Listed Sponsors
lead

R-Pharm

INDUSTRY